Answers are grounded in this paper and cite their sources.
There is variation in cardiorespiratory monitoring practices for neonatal abstinence syndrome. We examined the incidence of cardiorespiratory adverse events in infants with neonatal abstinence syndrome who were treated or nontreated pharmacologically. Eight (10%) in the nontreated and 23 (19%) in the treated group experienced adverse events. This warrants further investigation in a larger cohort.
No takes yet. Share an insight, caveat, or question.
Davala et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: